Catalyst ligands

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The y-carbaldehyde intermediates (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (35.7 mg, 71.0 mumol) in MeOH (1.0 mL) and AcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (8.90 mg, 142 mumol) was added slowly to the reaction mixture and stirred at room temperature for 24 h. The reaction mixture was poured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was then washed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain the corresponding tri-N-Boc-protected amine intermediates (68.9 mg), which were used in the next step without purification. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 6-12.

170161-27-0, The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1120-02-1, OctMAB is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: In a typical synthesis of DA-La(PW11)2, an aqueous solution of (2.0 g, 0.31 mmol) K-La(PW11)2 was dropped into a chloroform solution of (1.1 g, 3.75 mmol) DA-Br. A white precipitate formed after the addition of the whole K-La(PW11)2 aqueous solution and then the product was separated after a further 1 h of stirring. The product was washed twice with H2O and dried in air [9]. DDA-La(PW11)2, TDA-La(PW11)2, HDA-La(PW11)2 and ODA-La(PW11)2 were prepared with a similar procedure. In the 1H NMR spectra, the singlet peak at 2.5 ppm and 3.3 ppm is assigned to be DMSO-d6, and the water in DMSO-d6, respectively.

1120-02-1, The synthetic route of 1120-02-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Zhao, Shen; Jia, Yueqing; Song, Yu-Fei; Applied Catalysis A: General; vol. 453; (2013); p. 188 – 194;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.112881-51-3,4′-(4-Pyridyl)-2,2′:6′,2”-terpyridine,as a common compound, the synthetic route is as follows.

Cd(NO3)2¡¤4H2O (123mg, 0.4mmol),4?-(4-pyridyl)-2.2?:6?,2??-terpyridine (31 mg, 0.1 mmol) were added to a mixture ofH2O (5 mL) and DMF (1 mL). The slurry was then transferred into a 23 mL Teflonlinedautoclave and heated at 110 C for 48 h. The solution was allowed to cool at arate of 5 C/h to room temperature. Neddle-shaped crystals were collected throughfiltration, washed with H2O (3 ¡Á 20mL) and EtOH(3 ¡Á 20 mL), dried at roomtemperaturein a vacuum(47 mg, 85% yield based on PYTPY). IR (KBr): nu=3455 (vw),3060 (w), 2800 (vw), 1600 (vs), 1450 (vs), 1378 (vs), 1291 (vs), 1166 (m), 1080(w), 1007 (m), 894 (w), 835 (w), 789 (m), 723 (w), 650 (m), 583 (vw), 498(w) cm-1. C21H17CdN5O6 (M = 547.80): calcd. C 45.90%, H3.120%, N 12.75%;found: C 45.76%, H3.143%, N 12.96%., 112881-51-3

The synthetic route of 112881-51-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Yuan, Lijun; Fu, Zhiyong; Inorganic Chemistry Communications; vol. 69; (2016); p. 66 – 69;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5,4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a solution of 1,4,7-triazacyclononane (2 mmol) in distilled ethanol (50 mL) containing molecular sieve was added 1 equiv of aldehyde. The reaction mixture was stirred at room temperature. The solution was filtered and the filtrate was evaporated under reduced pressure to yield the aminal adduct.

As the paragraph descriping shows that 4730-54-5 is playing an increasingly important role.

Reference£º
Article; Roger, Melissa; Patinec, Veronique; Bourgeois, Martine; Tripier, Raphael; Triki, Smail; Handel, Henri; Tetrahedron; vol. 68; 27-28; (2012); p. 5637 – 5643;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.29176-55-4,2,9-Dichloro-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: Diaryl-substituted phenanthrolines were prepared by combining thedihalo-substituted phenanthroline with the appropriate phenylboronicacid in a 100 mL Schlenk flask. The solids were suspended in 30 mL oftoluene and 20 mL of 2 M Na2CO3(aq), then purged with Ar for 15 min.Subsequently, Pd(PPh3)4 (0.175 g, 0.15 mmol) was added to the flask,purged for an additional 15 min, then heated at reflux under Ar whilerapidly stirring. After 48 h, the biphasic mixture was cooled to roomtemperature and the two layers were isolated. The aqueous layer waswashed with dichloromethane and all organic fractions were combined,dried using anhydrous MgSO4, and filtered. The solvent was removedby rotary evaporation, and the solids were recrystallized with minimaltoluene followed by vacuum filtration. If necessary, the volume of theresulting filtrate was reduced and hexanes added to induce precipitation.The mixture was vacuum filtered and resulting white solids were collected., 29176-55-4

As the paragraph descriping shows that 29176-55-4 is playing an increasingly important role.

Reference£º
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

(e) Synthesis of BRI7160 and BRI7161; The compounds were prepared according to Reaction Scheme 4: Compound 4 was prepared following the method of R. Guilard et al., Bull. Soc. Chim. Fr., 1996, 133, 65-73.A magnetically stirred suspension of compound 4 (430 mg, 0.86 mmol), (4-bromomethyl) methyl benzoate (217 mg, 0.95 mmol), KHCO3 (172 mg) and K2CO3 (174 mg) in dry acetonitrile (17 ml) was heated at reflux for 18 h under an atmosphere of nitrogen. The reaction mixture was cooled to room temperature then concentrated under reduced pressure to yield a straw coloured oil which was purified by flash chromatography (silica, 5% methanol/dichloromethane elution). Concentration of the appropriate fractions (RF 0.38) afforded adduct 5a as a clear, colourless oil. Mass Spectrum (APCI) m/z 649 [(M+H)+, 100%]., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Patent; Prana Biotechnology Ltd; US7704987; (2010); B1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.17217-57-1,4,4′-Dimethoxy-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

General procedure: The synthesis of complexes was carried out by single potsynthesis. An anhydrous methanolic solution (10 mL) of 4-fluoro-N-salicylideneaniline (0.6456, 3 mmol) was addeddropwise to a vigorously stirred solution of 2,2?-bipyridine(0.1561, 1 mmol) in 10 mL methanol. To this solution ofligands, a methanolic solution of EuCl3 (0.2583 g, 1 mmol)was added slowly with continuous stirring. The pH of thereaction mixture obtained was adjusted to 6.0?7.0. Afteradjusting the pH, the reaction mixture was refluxed at 60 ¡ãC.The refluxing was continued for 5 h. The light yellow solutionso obtained was evaporated at room temperature to give thesolid compound which was extracted with diethyl ether. Thecompound obtained after extraction is C1 (Scheme 1).

17217-57-1, 17217-57-1 4,4′-Dimethoxy-2,2′-bipyridine 2733927, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Sengar, Manju; Narula, Anudeep Kumar; Journal of Fluorescence; vol. 29; 1; (2019); p. 111 – 120;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4199-88-6,5-Nitro-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

General procedure: A 0.5 mmol quantity of copper(II) nitrate trihydrate was treated with 1.0 mmol of phen (or nphen) in ethanol (20 ml) under stirring conditions for 0.5 h. The product was isolated, washed with ethanol and set aside for crystallization by slow evaporation at room temperature. Green crystals were crystallized from the solution after a week. The structure of [Cu(phen)2(H2O)](NO3)2 has been previously determined by Nakai and Deguchi [43], by Catalan et al. [44], by Szpakolski et al. [45], by Zhou [46] and by Boutebdja et al. [47]. Complex 1: Yield was 87%. Anal. Calcd. for C24 H18 Cu N8 O12 (673.99 g mol-1) (%): C, 43.18; H, 2.67; N,16.63. Found: C, 42.77; H, 2.69; N, 16.63.

4199-88-6, The synthetic route of 4199-88-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Inci, Duygu; Aydin, Rahmiye; Vatan, Oezguer; Yilmaz, Dilek; Genckal, Hasene Mutlu; Zorlu, Yunus; Cava?, Tolga; Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy; vol. 145; (2015); p. 313 – 324;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

787-70-2, [1,1′-Biphenyl]-4,4′-dicarboxylic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,787-70-2

Manganese(II) chloride (0.075 mmol, 10 mg), dipyridylacetylene(0.075 mmol, 14 mg) and biphenyl-4,4?-dicarboxylic acid (0.075 mmol, 18 mg) were suspendedin a mixture of dimethylformamide (8 mL), water (1 mL)and ethanol (1 mL) in a glass autoclave. The closed vesselwas then heated at 110 C over a period of 3 days. Then,the mixture was allowed to cool to rt in a rate of 5 C h-1,whereupon long needles formed which were filtered offand subjected to single crystal X-ray diffraction. Yield:14 mg (58%); dec. < 379 C. As the paragraph descriping shows that 787-70-2 is playing an increasingly important role. Reference£º
Article; Smeyanov, Alexey; Nieger, Martin; Gustus, Rene; Maus-Friedrichs, Wolfgang; Schmidt, Andreas; Zeitschrift fur Naturforschung, B: Chemical Sciences; vol. 70; 12; (2015); p. 897 – 902;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Compound 43 (50 mg, 0.063 mmol) and (3-bromopropyl)- trimethylammonium bromide (164mg, 0.63 mmol, LOEQV.) are dissolved and potassium carbonate (130 mg, 0.95 mmol, 15 eqv. ) is suspended under argon in absolute DMF (30 ML) and the mixture is stirred at 55C for 12 h. The solvent is removed in vacuo at 50C and the residue applied to a pad (2 cm deep) of silica. The unreacted ammonium salts are washed off with methanol (lOOOmL) and the product is eluted with acetic acid: methanol: water (3: 2: 1 by vol. ). The solvent is removed under reduced pressure and the residue further purified by chromatography on a column (100G) of Sephadex LH-20 using n-butanol: water: acetic acid (4: 5: 1 by vol. , upper phase) as the eluent. The solvents are removed under reduced pressure and the residue dissolved in methanol and passed through a small column of anion exchange resin (Amberlite IRA 400, chloride form) using methanol as eluent. After evaporation of solvent, the crude product is dissolved in the minimum amount of methanol and diethylether (50 mL) added. The solution is centrifuged for 15 min. The supernatant liquid is evaporated to dryness and the residue dried at high vacuum to give the product as a violet solid. 1H-NMR : 5H (300MHZ, CD30D) : 0.90 (t, 3H, 3J= 7.5 Hz), 1.25-1. 41 (m, 8H), 1.45 (bs, 2H), 1.87 (bs, 2H), 2.38 (bs, 6H), 3,29 (bs, 27H), 3.67 (t, 6H, 3J= 7. 5 Hz), 4.01 (t, 2H, 3J= 7. 5 Hz), 4.30 (t, 6H, 3J= 7.5 Hz), 7.11 (d, 2H, 3J= 7.5 Hz), 7. 38 (d, 6H, 3J= 7.5 Hz), 7.95 (d, 2H, 3J= 7.5 Hz), 8.11 (d, 6H, 3J= 7. 5 Hz), 8.93 (bs, 8H)

3779-42-8, 3779-42-8 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide 151145, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI